NO326406B1 - Anvendelse av en LHRH-antagonist for fremstilling av medikament for behandling av infertilitet. - Google Patents
Anvendelse av en LHRH-antagonist for fremstilling av medikament for behandling av infertilitet. Download PDFInfo
- Publication number
- NO326406B1 NO326406B1 NO20005145A NO20005145A NO326406B1 NO 326406 B1 NO326406 B1 NO 326406B1 NO 20005145 A NO20005145 A NO 20005145A NO 20005145 A NO20005145 A NO 20005145A NO 326406 B1 NO326406 B1 NO 326406B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- infertility
- lhrh antagonist
- lhrh
- intrauterine insemination
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract description 13
- 239000002474 gonadorelin antagonist Substances 0.000 title claims description 13
- 230000036512 infertility Effects 0.000 title claims description 11
- 208000000509 infertility Diseases 0.000 title claims description 11
- 231100000535 infertility Toxicity 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 230000009027 insemination Effects 0.000 claims abstract description 14
- 230000000638 stimulation Effects 0.000 claims description 13
- 102000006771 Gonadotropins Human genes 0.000 claims description 8
- 108010086677 Gonadotropins Proteins 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 239000002622 gonadotropin Substances 0.000 claims description 8
- 229940094892 gonadotropins Drugs 0.000 claims description 8
- 230000016087 ovulation Effects 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 6
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 6
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 6
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 6
- 229960003608 clomifene Drugs 0.000 claims description 6
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 6
- 230000002611 ovarian Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 3
- 229960003230 cetrorelix Drugs 0.000 claims description 3
- 108700008462 cetrorelix Proteins 0.000 claims description 3
- 231100000673 dose–response relationship Toxicity 0.000 claims description 3
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical group C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
- 108010070670 antarelix Proteins 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 210000002394 ovarian follicle Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 6
- 239000005557 antagonist Substances 0.000 abstract description 2
- 108700012941 GNRH1 Proteins 0.000 abstract 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 5
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Fats And Perfumes (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Liquid Crystal Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8274398P | 1998-04-23 | 1998-04-23 | |
| PCT/EP1999/002133 WO1999055357A1 (en) | 1998-04-23 | 1999-03-29 | Method for the treatment of fertility disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005145D0 NO20005145D0 (no) | 2000-10-13 |
| NO20005145L NO20005145L (no) | 2000-10-13 |
| NO326406B1 true NO326406B1 (no) | 2008-11-24 |
Family
ID=22173160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005145A NO326406B1 (no) | 1998-04-23 | 2000-10-13 | Anvendelse av en LHRH-antagonist for fremstilling av medikament for behandling av infertilitet. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6319192B1 (es) |
| EP (1) | EP1082129B1 (es) |
| JP (1) | JP2002512975A (es) |
| KR (1) | KR100632722B1 (es) |
| AT (1) | ATE252910T1 (es) |
| AU (1) | AU752415B2 (es) |
| BR (1) | BR9909802A (es) |
| CA (1) | CA2330131C (es) |
| CZ (1) | CZ301912B6 (es) |
| DE (1) | DE69912422T2 (es) |
| DK (1) | DK1082129T3 (es) |
| ES (1) | ES2207941T3 (es) |
| HU (1) | HU228736B1 (es) |
| IL (1) | IL139027A0 (es) |
| NO (1) | NO326406B1 (es) |
| NZ (1) | NZ507405A (es) |
| PL (1) | PL195989B1 (es) |
| PT (1) | PT1082129E (es) |
| RU (1) | RU2221588C2 (es) |
| SI (1) | SI1082129T1 (es) |
| SK (1) | SK285192B6 (es) |
| TR (1) | TR200003063T2 (es) |
| UA (1) | UA66850C2 (es) |
| WO (1) | WO1999055357A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| EP0788799A3 (en) * | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| US8173592B1 (en) * | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
| US8465412B2 (en) * | 2001-01-12 | 2013-06-18 | Michael Levy | Uterine devices and method of use |
| US6758806B2 (en) | 2001-01-12 | 2004-07-06 | Napoli, Llc | Endoscopic devices and method of use |
| US6623422B2 (en) * | 2001-01-12 | 2003-09-23 | Napoli, Llc | Method and apparatus for assisted embryo implantation |
| US20060183973A1 (en) * | 2001-01-12 | 2006-08-17 | Kamrava Michael M | Endoscopic devices and method of use |
| CN1313059C (zh) * | 2001-01-12 | 2007-05-02 | 纳波利有限公司 | 一种用于内窥镜下胚胎移植的微型导液管 |
| WO2003051344A1 (en) * | 2001-12-14 | 2003-06-26 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation_using a non-polypeptide camp level modulator |
| US7033314B2 (en) * | 2002-01-11 | 2006-04-25 | Fidelitycorp Limited | Endoscopic devices and method of use |
| US20030186892A1 (en) * | 2002-03-28 | 2003-10-02 | Rajneesh Taneja | Enhancement of endogenous gonadotropin production |
| US6695766B2 (en) | 2002-04-26 | 2004-02-24 | Olympia Womens Health | Magnetic embryo transfer |
| EP1364658A1 (en) * | 2002-05-24 | 2003-11-26 | Applied Research Systems ARS Holding N.V. | Use of varying ratios of gonadotrophins in controlled ovarian hyperstimulation |
| MXPA04012246A (es) | 2002-06-07 | 2005-04-08 | Ares Trading Sa | Metodo para la hiperestimulacion ovarica controlada y equipo farmaceutico para usarlo en dicho metodo. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
| DE4305225A1 (de) | 1993-02-19 | 1994-08-25 | Asta Medica Ag | Neues Herstellverfahren für Cetrorelix Lyophilisat |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| EP0788799A3 (en) * | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| US5824548A (en) * | 1996-05-29 | 1998-10-20 | Wisconsin Alumni Research Foundation | Method of increasing survival of cultured primate embryos in medium containing exogenous gonadotrophin releasor hormone |
| DE19712718C2 (de) * | 1997-03-26 | 1999-09-23 | Asta Medica Ag | Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung |
| US5961444A (en) * | 1997-10-17 | 1999-10-05 | Medworks Corporation | In vitro fertilization procedure using direct vision |
-
1999
- 1999-03-29 WO PCT/EP1999/002133 patent/WO1999055357A1/en active IP Right Grant
- 1999-03-29 PT PT99919152T patent/PT1082129E/pt unknown
- 1999-03-29 BR BR9909802-4A patent/BR9909802A/pt not_active Application Discontinuation
- 1999-03-29 HU HU0101528A patent/HU228736B1/hu unknown
- 1999-03-29 NZ NZ507405A patent/NZ507405A/xx not_active IP Right Cessation
- 1999-03-29 AU AU37028/99A patent/AU752415B2/en not_active Expired
- 1999-03-29 CA CA2330131A patent/CA2330131C/en not_active Expired - Lifetime
- 1999-03-29 DE DE69912422T patent/DE69912422T2/de not_active Expired - Lifetime
- 1999-03-29 RU RU2000129658/14A patent/RU2221588C2/ru active
- 1999-03-29 KR KR1020007011649A patent/KR100632722B1/ko not_active IP Right Cessation
- 1999-03-29 JP JP2000545555A patent/JP2002512975A/ja active Pending
- 1999-03-29 IL IL13902799A patent/IL139027A0/xx not_active IP Right Cessation
- 1999-03-29 TR TR2000/03063T patent/TR200003063T2/xx unknown
- 1999-03-29 DK DK99919152T patent/DK1082129T3/da active
- 1999-03-29 AT AT99919152T patent/ATE252910T1/de active
- 1999-03-29 SI SI9930448T patent/SI1082129T1/xx unknown
- 1999-03-29 SK SK1530-2000A patent/SK285192B6/sk not_active IP Right Cessation
- 1999-03-29 PL PL99343609A patent/PL195989B1/pl unknown
- 1999-03-29 EP EP99919152A patent/EP1082129B1/en not_active Expired - Lifetime
- 1999-03-29 ES ES99919152T patent/ES2207941T3/es not_active Expired - Lifetime
- 1999-03-29 CZ CZ20003766A patent/CZ301912B6/cs not_active IP Right Cessation
- 1999-03-29 UA UA2000116510A patent/UA66850C2/uk unknown
- 1999-04-23 US US09/296,610 patent/US6319192B1/en not_active Expired - Lifetime
-
2000
- 2000-10-13 NO NO20005145A patent/NO326406B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Howles et al. | Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization programme | |
| Felberbaum et al. | Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists | |
| Diedrich et al. | New approaches to ovarian stimulation | |
| NO326406B1 (no) | Anvendelse av en LHRH-antagonist for fremstilling av medikament for behandling av infertilitet. | |
| US20110306547A1 (en) | Lhrh - antagonists in the treatment of fertility disorders | |
| Itskovitz-Eldor et al. | First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) | |
| AU2794100A (en) | Treatment of infertility | |
| EP1511537A2 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| Gianaroli et al. | Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles | |
| Dal Prato et al. | Live birth after IVF in a 46-year-old woman | |
| Ali et al. | Ovarian hyper-stimulation protocols in good prognosis patients: agonist versus antagonist protocol, an Iraqi view | |
| Ng et al. | Use of Gonadotrophin Releasing Hormone (GnRH) Antagonist (Cetrotide) during Ovarian Stimulation for in‐vitro Fertilization Treatment: Multiple Doses and Single Dose | |
| Felberbaum et al. | Are we on the verge of a new era in ART? | |
| Ho et al. | Natural Cycle and Minimal Stimulation IVF | |
| MXPA00010284A (es) | Metodo para el tratamiento de desordenes de la fertilidad | |
| Banker et al. | IVF Stimulation Protocols and Outcomes in Women with Endometriosis Check for updates | |
| Awwad | 29 ProgesteroneDaliaKhalife, NourAssaf | |
| Insler et al. | The combined pituitary suppression/ovarian stimulation therapy: myths and realities | |
| Nagori et al. | 6 Intrauterine Insemination | |
| EP1364658A1 (en) | Use of varying ratios of gonadotrophins in controlled ovarian hyperstimulation | |
| Sharma et al. | A NewShine on Intrauterine Insemination | |
| WO2021262186A1 (en) | Hp-hmg for use in the treatment of infertility in a patient with polycystic ovary syndrome | |
| Lele et al. | Agonist versus antagonist protocol in induction of ovulation and its outcome | |
| Yoldemir | ART sikluslarında stimulasyona başlamadan önce uzamış ovaryen süpresyonun gebelik oranlarına etkisi | |
| Davar et al. | Clinical Effects of a microdose GnRH agonist flare regimen administered to poor responders undergoing ART cycles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |